Biomodulatory Treatment of Patients with Castration-Resistant Prostate Cancer: A Phase II Study of Imatinib with Pioglitazone, Etoricoxib, Dexamethasone and Low-Dose Treosulfan
| Autor: | K. Schmidt, M. Baier, Reinhard Andreesen, S. Feyerabend, Katrin Birkholz, R. Oberneder, W. F. Wieland, A. Bakhshandeh-Bath, A. Ruebel, S. Mueller, Wolfgang Herr, H. Heinzer, Albrecht Reichle, Arnulf Stenzl, T. Suedhoff, F. Eichhorn, J. Huebner, Martin Vogelhuber, M. Schulze |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Quality of life
Cancer Research medicine.medical_specialty Population Urology Phases of clinical research Treosulfan urologic and male genital diseases Clinical endpoint Medicine education Castration-resistant prostate cancer education.field_of_study business.industry PSA response Surgery Regimen Imatinib mesylate Oncology Multi-targeted biomodulatory therapy Concomitant Original Article Erratum business Etoricoxib medicine.drug |
| Zdroj: | Cancer Microenvironment |
| ISSN: | 1875-2292 |
| Popis: | Therapeutic options for patients with castration-resistant prostate cancer (CRPC) remain limited. In a multicenter, Phase II study, 65 patients with histologically confirmed CRPC received a biomodulatory regimen during the six-month core study. Treatment comprised daily doses of imatinib mesylate, pioglitazone, etoricoxib, treosulfan and dexamethasone. The primary endpoint was prostate-specific antigen (PSA) response. Responders could enter an extension phase until disease progression or intolerable toxicity occurred. Mean PSA was 45.3 ng/mL at baseline, and 77 % of patients had a PSA doubling time |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink